Fairness Opinion

Duff & Phelps Provided a Fairness Opinion to the Board of Directors of Chiasma, Inc. on Its Sale to Amryt Pharma plc

On May 4, 2021, Chiasma, Inc. (NASDAQ: CHMA), a Newton, Massachusetts-based biopharmaceutical company, signed a definitive merger agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, in an all-stock deal.

Duff & Phelps, A Kroll Business, served as a financial advisor to the board of directors of Chiasma and provided an independent fairness opinion in connection with the transaction.

About Chiasma, Inc. (NASDAQ: CHMA)
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. Goodwin Procter LLP served as legal counsel to Chiasma.

About Amryt Pharma plc (NASDAQ: AMYT, AIM: AMYT)
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Gibson, Dunn & Crutcher LLP served as legal counsel to Amryt.



Fairness and Solvency Opinions

Duff & Phelps Opinions is a global leader in Fairness Opinions and Special Committee Advisory, ranking #1 for total number of fairness opinions in the U.S., EMEA (Europe, the Middle East and Africa), Australia and Globally in 2023 according to LSEG (FKA Refinitiv).

SPAC Advisory Services

Focused expertise for SPAC transactions.

Private Capital Markets – Debt Advisory

Kroll has extensive experience raising capital for middle-market companies to support a wide range of transactions.


Mergers and Acquisitions (M&A) Advisory

Kroll’s investment banking practice has extensive experience in M&A deal strategy and structuring, capital raising, transaction advisory services and financial sponsor coverage.

Transaction Advisory Services

Kroll’s Transaction Advisory Services platform offers corporate and financial investors with deep accounting and technical expertise, commercial knowledge, industry insight and seamless analytical services throughout the deal continuum.

See All Case Study